Breast Cancer | Specialty

Significant Changes to Reimbursement Rates in Breast Cancer for 2014

December 31st 2013

Although the changeover to using ICD-10 billing codes won't be mandatory until October 1, 2014, there are many coding changes to consider starting on January 1. Specifically, the reimbursement rate for some genetic testing and imaging involving breast cancer will see significant changes.

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20th 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

Managing Bone Health in Advanced Lung Cancer

December 19th 2013

Managing Bone Health in Breast Cancer

December 19th 2013

Managing Bone Health in Prostate Cancer

December 19th 2013

FALCON Trial Compares Two Types of Endocrine Therapy

December 19th 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

Dr. Neumayer Discusses the POWER PIINC Trial

December 18th 2013

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Dr. Turner Discusses the PALOMA-3 Trial

December 17th 2013

Nicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Dr. Garner Discusses the myRisk Hereditary Cancer Test

December 16th 2013

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status

December 16th 2013

Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.

Dr. Esserman Discusses the I-SPY 2 Trial

December 16th 2013

Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Dr. Brenner on the Link Between Breast Cancer and Obesity

December 13th 2013

Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.

Dr. Julie Gralow Discusses the SWOG S0500 Trial

December 13th 2013

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC

December 13th 2013

The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.

Ramucirumab Does Not Prolong PFS in HER2-Negative Metastatic Breast Cancer

December 13th 2013

Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.

CTCs Prognostic But Not Helpful In Switching Therapy in MBC

December 13th 2013

Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

Carboplatin Improves pCR More Than Bevacizumab in TNBC

December 13th 2013

The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.

BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable

December 13th 2013

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC

December 13th 2013

Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Dr. Matthew Ellis Discusses the FALCON Trial

December 13th 2013

Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.